Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $39.38 USD
Change Today +0.87 / 2.26%
Volume 624.7K
SGEN On Other Exchanges
As of 8:10 PM 10/9/15 All times are local (Market data is delayed by at least 15 minutes).

seattle genetics inc (SGEN) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/20/15 - $52.33
52 Week Low
01/16/15 - $30.05
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for SEATTLE GENETICS INC (SGEN)

seattle genetics inc (SGEN) Related Businessweek News

View More BusinessWeek News

seattle genetics inc (SGEN) Details

Seattle Genetics, Inc., a biotechnology company, develops and commercializes antibody-based therapies for the treatment of cancer. The company is developing antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. Its lead product, ADCETRIS (brentuximab vedotin), is an ADC that is commercially available in approximately 55 countries, including the United States, Canada, Japan, and members of the European Union for relapsed Hodgkin lymphoma (HL) and relapsed systemic anaplastic large cell lymphoma (sALCL) in collaboration with Takeda Pharmaceutical Company Limited. The company is evaluating ADCETRIS in approximately 30 ongoing clinical trials, including Phase III trials for post-transplant HL relapse prevention, relapsed CD30-positive cutaneous T-cell lymphoma, frontline HL in combination with chemotherapy, and frontline CD30-positive mature T-cell lymphoma in combination with chemotherapy, as well as in Phase I and II studies in various lymphoma and non-lymphoma indications. In addition, it is developing a pipeline of other clinical-stage programs, including SGN-CD19A for CD19A-positive hematologic malignancies; SGN-CD33A in CD33-positive acute myeloid leukemia; SGN-LIV1A in LIV-1-positive breast cancer; ASG-22ME for the treatment of Nectin-4-positive solid tumors; ASG-15ME for treatment of SLITRK6-positive bladder cancer; and SEA-CD40, a non-fucosylated antibody utilizing a novel immuno-oncology technology. The company has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie, Bayer, Genentech, GlaxoSmithKline, and Pfizer. Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.

657 Employees
Last Reported Date: 02/27/15
Founded in 1998

seattle genetics inc (SGEN) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: $759.3K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $422.1K
Chief Operating Officer
Total Annual Compensation: $472.3K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $448.0K
Executive Vice President of Process Sciences ...
Total Annual Compensation: $378.4K
Compensation as of Fiscal Year 2014.

seattle genetics inc (SGEN) Key Developments

Seattle Genetics Announces Initiation of Phase 1/2 Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Combination with Opdivo® (Nivolumab) in Second-Line Hodgkin Lymphoma

Seattle Genetics, Inc. announced that it has initiated a phase 1/2 clinical trial of ADCETRIS (brentuximab vedotin) in combination with Opdivo (nivolumab) for patients with relapsed or refractory Hodgkin lymphoma (HL) after failure of frontline treatment. The trial is being conducted under a previously announced clinical trial collaboration agreement with Bristol-Myers Squibb Company. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, a defining marker of classical HL, which combines the targeting ability of a monoclonal antibody with a highly potent cell-killing agent. Opdivo is a human antibody that targets and inhibits the programmed death receptor-1 (PD-1), resulting in T-cell activation. Opdivo is part of a new class of cancer immunotherapy treatments known as checkpoint inhibitors, which are designed to harness the body’s own immune system in fighting cancer by targeting distinct regulatory components of the immune system. A second trial under the collaboration is planned to begin later in 2015 for relapsed or refractory B-cell and T-cell non-Hodgkin lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL). The phase 1/2 open-label trial will enroll relapsed or refractory HL patients who have failed frontline therapy. The primary objective is to assess the safety and antitumor activity of ADCETRIS in combination with Opdivo. After completion of four cycles of combination therapy, patients are eligible to undergo autologous stem cell transplant (ASCT). Patients at high risk of relapse or progression following ASCT will be eligible to receive ADCETRIS in the commercial setting. All patients will be assessed for progression-free survival after ASCT. The trial is being conducted at multiple centers in the United States and is designed to enroll up to approximately 60 patients.

Seattle Genetics Announces FDA Regular Approval of ADCETRIS® (Brentuximab Vedotin) for Classical Hodgkin Lymphoma Patients at High Risk of Relapse or Progression as Post-Autologous Hematopoietic Stem Cell Transplantation Consolidation

Seattle Genetics, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved ADCETRIS (brentuximab vedotin) for the treatment of patients with classical Hodgkin lymphoma (HL) at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation. The approval is based on a phase 3 clinical trial called AETHERA that was designed to compare up to 16 cycles (approximately one year) of ADCETRIS therapy administered every three weeks following auto-HSCT to placebo. The primary endpoint was met with a significant improvement in median progression-free survival (PFS) of 42.9 months (95% CI: 30.4, 42.9) for patients who received ADCETRIS versus 24.1 months (95% CI: 11.5, not estimable) for patients who received placebo, an improvement of 18.8 months (hazard ratio=0.57 [95% CI: 0.40, 0.81]; p-value=0.001). In addition, data from the AETHERA trial converted the U.S. accelerated approval of the relapsed classical HL indication to regular approval. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, which is expressed in classical HL and systemic anaplastic large cell lymphoma (sALCL), as well as other lymphoma subtypes. This is the third indication for ADCETRIS, which was granted accelerated FDA approval in August 2011 for two other indications: (1) treatment of Hodgkin lymphoma patients who fail autologous transplant or who fail at least two prior multi-agent chemotherapy regimens and are not autologous transplant candidates, and (2) treatment of systemic ALCL patients who fail at least one prior multi-agent chemotherapy regimen. The sALCL indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Seattle Genetics, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Revises Sales Guidance for the Year of 2015

Seattle Genetics, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenues of $77,096,000 against $68,308,000 a year ago. Loss before income taxes was $47,563,000 against $17,643,000 a year ago. Net loss was $47,502,000 or $0.38 per basic and diluted share against $17,590,000 or $0.14 per basic and diluted share a year ago. For the six months, the company reported total revenues of $159,253,000 against $136,579,000 a year ago. Loss before income taxes was $69,306,000 against $34,014,000 a year ago. Net loss was $69,192,000 or $0.55 per basic and diluted share against $33,891,000 or $0.28 per basic and diluted share a year ago. The company anticipates that 2015 revenues from ADCETRIS net product sales in the U.S. and Canada will be slightly higher than previously anticipated, and are now expected to be in the range of $210 million to $220 million.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SGEN:US $39.38 USD +0.87

SGEN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Genmab A/S kr622.00 DKK -3.00
Insys Therapeutics Inc $25.65 USD +0.64
Medivation Inc $41.26 USD +2.03
MorphoSys AG €60.46 EUR -0.73
Pfizer Ltd/India 2,449 INR 0.00
View Industry Companies

Industry Analysis


Industry Average

Valuation SGEN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 15.9x
Price/Book 27.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 16.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SEATTLE GENETICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at